This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Eton Pharmaceuticals Announces CFO Succession
Business CFO succession

Eton Pharmaceuticals Announces CFO Succession

Analysis based on 7 articles · First reported Apr 16, 2026 · Last updated Apr 16, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The planned CFO succession at Eton Pharmaceuticals is generally viewed positively, as it brings in an experienced executive, Judith M. Matthews, to support the company's growth. This move is expected to have a minor positive impact on Eton Pharmaceuticals' stock price, reflecting confidence in its future financial leadership.

Pharmaceuticals
Event Summary

Eton Pharmaceuticals announced a planned CFO succession. Judith M. Matthews has been appointed Executive Vice President, Accounting and Finance, and will assume the role of Chief Financial Officer effective June 1, 2026. The current CFO, James Gruber, will step down on May 31, 2026, and will enter into a six-month consulting agreement with Eton Pharmaceuticals to ensure a seamless transition. Sean Brynjelsen, CEO of Eton Pharmaceuticals, welcomed Judith M. Matthews, highlighting her extensive experience in pharmaceutical finance, and thanked James Gruber for his four years of service. Judith M. Matthews previously served as CFO of Iterum Therapeutics plc and was VP of Finance at Durata Therapeutics.

Entities Involved
stock
Eton Pharmaceuticals
Eton Pharmaceuticals announced a planned CFO succession, with Judith M. Matthews taking over from James Gruber, aiming to support its next phase of growth in rare diseases.
Importance 100.0 Sentiment 10.0
per
Judith M. Matthews
Judith M. Matthews is appointed Executive Vice President, Accounting and Finance, and will become the new Chief Financial Officer of Eton Pharmaceuticals, bringing over 25 years of finance leadership experience.
Importance 90.0 Sentiment 20.0
per
James Gruber
James Gruber will step down as CFO of Eton Pharmaceuticals as part of a planned succession and will enter into a six-month consulting agreement to ensure a smooth transition.
Importance 70.0 Sentiment 0.0
per
Sean Brynjelsen
Sean Brynjelsen, CEO of Eton Pharmaceuticals, expressed pleasure in welcoming Judith M. Matthews and thanked James Gruber for his contributions.
Importance 30.0 Sentiment 0.0
stock
Iterum Therapeutics
Judith M. Matthews previously served as Chief Financial Officer of Iterum Therapeutics plc.
Importance 10.0 Sentiment 0.0
priv
Durata Therapeutics
Judith M. Matthews was Vice President of Finance at Durata Therapeutics until its acquisition by Teva Pharmaceuticals.
Importance 10.0 Sentiment 0.0
stock
Teva Pharmaceuticals
Teva Pharmaceuticals acquired Durata Therapeutics, where Judith M. Matthews previously worked.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.